Cardurion
cardurion.com
Actively hiring
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$260M
1 round on record
Latest round
$260M
Series B · Jul 2024 · 2 yr ago
Backers
2
GV, NEA
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 16, 2024
Raised a round Series B $260M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jul 2024 | $260M | — | fiercebiotech.com |
GV 
NEA Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Sequana Medical is a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer.
Therapeutic Ultrasound-Based Solution for Vascular Care. cardiovascular disease is VTE. ¹.
Replacing Hearts. Restoring Lives. HEART FAILURE Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2…
Imbria Pharmaceuticals is developing novel cardiovascular therapies targeting cardiac energy metabolism to address serious cardiovascular…
Gamma Diagnostics. Global experts in Gamma Prime Fibrinogen (GPF), a lifesaving biomarker for the prediction of clotting and inflammation…
845-359-2389 – The Optimizer® Smart is the first implantable device for the treatment of chronic heart failure in patients with normal QRS…
News
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Cardurion Pharmaceuticals, Inc. (
Read more
Report
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
Results from two Phase 2 clinical trials assessing tovinontrine in both major types of chronic heart failure will be presented at the Heart Failure Society of America annual scientific meeting
Read more
Report
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
Results from two Phase 2 clinical trials assessing tovinontrine in both major types of chronic heart failure will be presented at the Heart Failure Society of America annual scientific meeting BURLINGTON, Mass.- August 27, 2026 - Cardurion Pharmaceuticals
Read more
Report
Cardurion concludes enrolment in Phase II trials for heart failure treatment
The change in N-terminal pro B-type natriuretic peptide is the primary goal for both trials.
Read more
Report
Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure
Burlington, MA, August 6, 2025 - Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that i
Read more
Report
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
Burlington, Mass., March 20, 2025 - Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis
Read more
Report
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
Burlington, Mass., January 8, 2025 - Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (
Read more
Report
Cardurion Pharmaceuticals Selected as an Endpoints 11 Most Promising Biotech Company
Burlington, Mass., September 27, 2024 - Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has been named as o
Read more
Report
Cardurion Pharmaceuticals Appoints Ron Renaud to Board of Directors
Veteran biotech industry leader joins as company enters next stage of growth BURLINGTON, Mass. - September 26, 2024 -Cardurion Pharmaceuticals, Inc. ("Cardurion" or "the Company"), a clinical-stage biotechnology company developing next-generation therapeu
Read more
Report
Cardurion heads crop of sizeable bio financings
This week saw four nine-figure biotech financing rounds, for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio
Read more
Report
Show more news
Financials
Total raised
$260M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2024 | $260M | Details |